Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Prognostic value of the CRM status in pancreatic ductal adenocarcinoma: Data from a regional cancer registry.
Authors
Philipp Morakis
Geschäftsstelle Qualitätskonferenzen bei der Klinischen Landesregisterstelle Baden-Württemberg GmbH, Krebsregister Baden-Württemberg, Stuttgart, Germany
Philipp Morakis , Irina Surovtsova , Jasmin Schuhbaur , Daria Kokh , Claudia Winzler , Gertrud Szotyori-Artz , Juliane Schütz , Waldemar Uhl , Andrea Tannapfel , Thomas Seufferlein
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 632)
DOI
10.1200/JCO.2024.42.3_suppl.632
Abstract #
632
Poster Bd #
K1
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Phase II study of the safety and efficacy of discontinuing pegfilgrastim for pancreatic adenocarcinoma treated with FOLFIRINOX.
First Author: Masahiro Yanagi
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Effect of resection margin status on recurrence pattern and survival in distal pancreatectomy for left-sided pancreatic ductal adenocarcinoma.
First Author: Jaewoo Kwon
Poster
2020 ASCO Virtual Scientific Program
A randomized phase II study of second-line treatment with liposomal irinotecan, and S-1 versus liposomal irinotecan and 5-fluorouracil in gemcitabine-refractory metastatic pancreatic cancer patients.
First Author: Esther Pijnappel
Poster
2020 Gastrointestinal Cancers Symposium
Tyme-88-Panc Part 2: A randomized phase II/III of SM-88 with MPS as third-line in metastatic PDAC.
First Author: Shubham Pant